Merck Invests € 290 Million in U.S. Drug Safety Testing Capacity
Responds to growing global demand for biosafety testing as essential requirement for drug development and commercialization
Merck invests more than € 290 million in its biosafety testing capacity at Rockville, Maryland, USA. This will significantly increase the company’s ability to conduct biosafety testing and analytical development services. Biosafety testing and analytical development are critical and fundamental requirements of the drug development and commercialization process to ensure the safety of medicines. Global demand for these services is growing at a double-digit rate.
Merck scientist counts cells in a cell culture lab in Rockville, Maryland, USA
Merck KGaA
“Merck is harnessing its broad portfolio of modern technologies and enabling services to help ensure the safety of the world’s medicines. These significant investments in Rockville and other sites across our global network will help us meet growing demand for the robust testing studies that biologics manufacturers depend upon to comply with stringent regulatory guidelines,” said Belén Garijo, Chair of the Executive Board and CEO of Merck. “This is a prime example of our focus on sustainable growth in areas with strong underlying upwards dynamics.”
“This is the largest investment in contract testing in Merck’s history. Our Rockville campus has a long track record of testing for both traditional and novel therapies. We have been driving innovation in biosafety testing for 75 years and this expansion enables Merck to lead in shaping the future of testing,” said Matthias Heinzel, Member of the Executive Board of Merck and CEO Life Science. “We thank the State of Maryland and Montgomery County, Maryland, for their collaboration in making this new campus a reality for our employees and clients. Together, we are impacting life and health with science.”
The BioReliance® contract testing portfolio from Merck provides biosafety testing and analytical development methods for both traditional and novel therapies. The new state-of-the-art, 23,000-square-meter facility at Merck’s Rockville site will house biosafety testing, analytical development, viral clearance suites, and cell bank manufacturing services. Currently, about 600 employees work at the site. Over the next four years, the expansion will create more than 500 new jobs.
With more than 30 years of drug development, material science and process technology expertise, Millipore® CTDMO Services offerings span pre-clinical development to commercial manufacturing, including testing, across multiple modalities including mAbs, highly potent active pharmaceutical ingredients, antibody-drug conjugates, viral vector therapies, mRNA, and lipid nanoparticle formulation.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Researchers create human airway stem cells from patients' cells - Advancing regenerative research for lung diseases, results could lead to new treatments for airways and lungs damaged by COVID-19, influenza, asthma and cystic fibrosis
Stanford Scientists Pinpoint Key Proteins in Blood Stem Cell Replication
List_of_subjects_in_Gray's_Anatomy:_IV._Myology
List_of_subjects_in_Gray's_Anatomy:_X._The_Organs_of_the_senses_and_the_Common_integument
Actelion's ponesimod successful in mid-stage trial in patients with plaque psoriasis - Ponesimod to proceed to Phase III clinical development in psoriasis
Gifted guardians of life and the environment: Europe honours the inventors of the year
Exonhit Enters Into Research Agreement With Pfizer to Identify Alzheimer’s Disease Biomarkers
Evonik to double its L-lysine capacities in the U.S. - First additional quantities expected in November 2011
How old memories fade away - Discovery of a gene essential for memory extinction could lead to new PTSD treatments
Silicone Breast Implants with Spider Silk-Based Coating Show Reduced Side-Effects in Preclinical Studies
Underlying molecular mechanism of bipolar disorder revealed
